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Tuberculosis (TB) remains one of the world's major health burdens with 9.6 million new infections
globally. Though considerable progress has been made in reduction of TB incidence and mortality, there
is a continuous need for lower cost, simpler and more robust means of diagnosis. One method that may
fulﬁl these requirements is in the area of breath analysis. In this study we analysed the breath of 21
patients with pulmonary or extra-pulmonary TB, recruited from a UK teaching hospital (University
Hospital Coventry and Warwickshire) before or within 1 week of commencing treatment for TB. TB
diagnosis was conﬁrmed by reference tests (mycobacterial culture), histology or radiology. 19 controls
were recruited to calculate speciﬁcity; these patients were all interferon-gamma release assay negative
(T.SPOT®.TB, Oxford Immunotec Ltd.). Whole breath samples were collected with subsequent chemical
analysis undertaken by Ion Mobility Spectrometry. Our results produced a sensitivity of 81% and a
speciﬁcity of 79% for all cases of TB (pulmonary and extra-pulmonary). Though lower than other studies
analysing pulmonary TB alone, we believe that this technique shows promise, and a higher sensitivity
could be achieved by further improving our sample capture methodology.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Major advances have been made in TB diagnosis, treatment and
mortality since the turn of the century, and the Millennium
Development Goal to halt and reverse TB incidence by 2015 has
partially been met. Despite this, in 2014 there were still an esti-
mated 9.6 million new TB cases, with 1.5 million deaths [1]. Whilst
the majority of those affected are from low- and middle-income
countries, the signiﬁcant burden of co-infection with TB and HIV(A.S. Sahota), ravi.gowda@
Arasaradnam@warwick.ac.uk
ulton), R.S.Savage@warwick.
R. Skinner), Emily.Adams@
(S.A. Ward), J.A.Covington@
r Ltd. This is an open access article(Human Immunodeﬁciency Virus), multi-drug resistance, along-
side widespread migration, has resulted in TB remaining a global
health concern. A newambition to end the TB epidemic by 2030 has
been set as part of the post-2015 global TB strategy [1]. To achieve
this Sustainable Development Goal, the vision of the World Health
Organisation (WHO) is for everyone to have access to innovative
tools and services required for rapid diagnosis, treatment and care.
In line with this, breath analysis for TB diagnosis (within minutes)
as opposed to standard microbiological culture, which can take up
to 2 months, is attractive.
Breath analysis utilises the detection of volatile organic com-
pounds (VOCs), gaseous chemicals that are the endogenous prod-
ucts of metabolism of individual microbes and whole organ
systems. It has many advantages for diagnostics e it is rapid, non-
invasive, acceptable to patients, and sample volumes are both un-
limited and can be given at will [2]. Importantly, analysis of breath
is thought to allow access to chemical processes not only in theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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duced directly in the lung, or reach lung tissue via blood through
the internal metabolic pathways of respiration. This allows a
wholesale comparison of chemical differences in health and a
number of diseased states, including infection and malignancy.
For this reason, many researchers have undertaken chemical
analysis of breath by various analytical means, with GCMS (Gas
Chromatography Mass Spectrometry) being the most popular. The
body of literature on GCMS has identiﬁed the key gas-phase bio-
markers and supports the hypothesis for breath as a potential tool
for TB diagnosis [3,4]. However, GCMS is a laboratory-based tech-
nique, with equipment being bulky, having a high unit cost, and
requiring trained staff and considerable infrastructure. Therefore
others have looked into alternative gas analysis techniques with
varying success. The electronic nose, ﬁrst proposed in the 1980s,
does not attempt to identify speciﬁc chemicals in a sample (as with
GCMS), but instead analyses a sample as awhole (like the biological
nose) using an array of non-selective gas sensors and a pattern
recognition algorithm [5]. The technique can give an immediate
result, uses air as the carrier gas, and can be made portable, simple
to use, and at a unit-cost which is appropriate to the medical pro-
fession. To this end, there have been a number of published studies
using different electronic nose instruments for the detection of TB
biomarkers in both breath and sputum [6e8]. Though the studies
show promise, these instruments have limitations. Firstly, some are
based on sensors which rely on a chemical interaction between the
surface of the sensor and the complex chemical sample. The surface
layers succumb to long-term drift and are affected by changes in
sample humidity and temperature. This means regular re-training
of equipment is required to optimise performance. In addition,
sensor manufacturing is such that each instrument is different and
requires every instrument to be trained. An alternative approach is
to use GC separation followed by QCM (Quartz Crystal Microbal-
ance) detection. This instrument circumvents the aforementioned
problems, but the requirement for a continuous helium supply
restricts its use in resource-limited settings.
FAIMS (Field Asymmetric Ion Mobility Spectrometry) is a tech-
nique which is ﬁnding favour with researchers in the medical
profession [9,10]. Like an electronic nose it does not attempt to
identify speciﬁc chemicals within samples, but instead measures
the mobility (or movement) of ionised molecules in high electric
ﬁelds (kVolts). Pattern recognition techniques can then be applied
to identify underlying trends within the mobility data, which can
be correlated to the presence, or lack, of a disease process. Due to
their incredibly high sensitivity (parts per billion or lower), repro-
ducible results, use of air as the carrier gas, and portability, in-
struments using FAIMS have found favour with the military for the
detection of chemical warfare agents. As these instruments mea-
sure a physical rather than chemical property of a molecule, they
suffer far less from drift and instrument-to-instrument variability
[11]. In this paper we report on the use of FAIMS for the analysis of
breath in patients with conﬁrmed TB compared with healthy
controls.
2. Methodology
A commercial FAIMS unit was used (Lonestar, Owlstone UK)
employing an ultra-violet (UV) ionisation source. Although this
does not ionise the same range of chemicals as Ni63 (a radionuclide
and the most commonly used ionisation method), units with a UV
source can be used in UK hospitals without a special license and are
easily transported from site to site. In a FAIMS unit, the complex
mixture of gases containedwithin the sample (in our case breath) is
pushed into the instrument where it is then ionised. The ionised
sample then passes between two “separator” plates, to which anoscillating asynchronous waveform is applied (typically GHz). Onto
these plates is applied a high positive potential for a short period of
time, followed by a small negative potential for a longer period of
time. Importantly, the applied amplitude  time are equal in both
cases. When in use, the ratio of short/high potential to longer/
smaller negative potential (described as the “dispersion ﬁeld”) is
cycled from1 up to the systemsmaximumvalue. In the electric ﬁeld
generated by these potentials, ions are attracted to, repelled by or
remain unaffected, depending upon the mobility difference be-
tween high- and low-ﬁeld regime. If an ion then touches one of the
plates it loses its charge, thus only ions with speciﬁc mobility exit
the plates, still with their charge, and are detected. By applying a
direct current (DC) voltage (called the compensation voltage) to
one of the plates, it is possible to remove this attraction and
repulsion, allowing more ions to be detected. This compensation
voltage is cycled between a positive and negative potential and
therefore for a certain compensation voltage, only chemicals with a
speciﬁc mobility will be detected. The mobility of an ion depends
on the mass, charge, size and shape, however as the ﬁeld and the
velocity are constant and we can relate the mobility to the velocity
using the equation:
v ¼ KE (1)
where v and K are the velocity and mobility of ion respectively and
E is the electric ﬁeld strength. Since velocity changes is not pro-
portional to the electric ﬁeld intensity variations, at higher electric
ﬁelds the ion mobility can be expressed by the following equation.
Kh ¼ K
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where Kh and K are the high-ﬁeld mobility and low-ﬁeld mobility
respectively. a and b are compound speciﬁc values which account
for high-ﬁeld mobility effect, N is carrier gas density number and E
is the electric ﬁeld strength. More details of this process can be
found in [12,13]. Typical breath outputs using a FAIMS instrument
are shown in [9].
We recruited 23 adults (aged over 18 years) with clinically
suspected pulmonary or extra-pulmonary TB (by constitutional
symptoms or abnormal chest X-ray) from a UK teaching hospital
(University Hospital Coventry and Warwickshire) over 6 months
(March to September 2014). They were recruited from rapid-access
TB clinics or in-patient admissions, before or within 1 week of
commencing anti-TB medication. Diagnosis was later conﬁrmed by
culture, histology or radiology in 21 cases (average age 47 (18e86),
5 smokers). 2 cases had an alternative infective diagnosis (1 bac-
terial pneumonia, 1 Staphylococcus aureus chronic hip osteomye-
litis). 17 healthy controls were recruited for comparison, all
interferon-gamma release assay negative (T.SPOT®.TB, Oxford
Immunotec Ltd.). These 2 suspected TB cases with alternative ﬁnal
diagnosis were added to the healthy control group to make a total
of 19 controls (average age 38 (24e63), 5 smokers). A summary of
cases by site of infection and culture result is shown in Table 1.
Scientiﬁc and ethical approval was obtained from the local
Research& Development Department and theWarwickshire Ethics
Committee (reference number: 09/H1211/38). Written informed
consent was obtained from all participants.
Participants were requested to refrain from eating and drinking
for 2 h before breath capture.Whole breath samples were collected,
with participants breathing through a standard mouthpiece into a
3L tedlar bag repeatedly until the bag was full. Whole breath was
used for simplicity, ease of capture, and to allow disposal of bags
after single use for infection control purposes. Samples were ana-
lysed within 2 h of collection using the Lonestar instrument
Table 1
Summary of cases by site of TB infection and culture result.
TB site Sample type Culture
positive
Culture
negative*
Total
Pulmonary Sputum 5 0 5
Bronchoalveolar lavage
ﬂuidy
2 2 4
Lymph node Tissue/pus 5 1 6
Spine/psoas
abscess
Pus 4 0 4
Joint Fluid 1 0 1
Otherx 0 1 1
Total 21
* Histological or radiological diagnosis.
y 1 patient: lung tissue.
x 1 patient: testicular TB.
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system and a pump on the exhaust to pull the sample through the
instrument. The bag output was connected in parallel to a split ﬂow
box containing a mass ﬂow controller fed by ﬁltered air. By con-
trolling the speed of the pump and setting the mass ﬂow controller
to a speciﬁc ﬂow, the ﬂow out of the bag remained constant at
200 ml/min with the ﬂow through the machine at 2 L/min. The
Lonestar was setup with a dispersion ﬁeld cycled between 0 and
100% in 51 steps, and the compensation voltage between 6 V
and þ6 V in 512 steps. This allowed two complete output cycles to
be collected.
The data from these experiments were processed using a pre-
viously developed algorithm described in [14]. In brief, each sample
run generated 52,224 data points in a 2Dmatrix of dispersion ﬁelds
and compensation voltages. First, a 2D wavelet transform (using
Daubechies D4 wavelets) was applied to each sample run. This
serves both as a data compression step, but also as a matched ﬁlter
which can preferentially extract the diffuse ‘peaks’ in the data
corresponding to different sets of chemical species. This has the
effect of concentrating the signal in a relatively small number of
wavelet coefﬁcients, thus greatly simplifying and improving the
subsequent analysis steps.
A threshold was then applied to the variance (across samples) of
each wavelet coefﬁcient, removing those coefﬁcients that vary by
only a very small amount (or not at all). This is known from (from
prior work with FAIMS) to remove only uninformative and/orFigure 1. Classiﬁcation probabilities for the control and TB groups. Applying a Wil-
coxon rank-sum test to the sets of classiﬁcation probabilities from the two groups, we
get a p-value of 2.89*106, showing that there is a highly statistically signiﬁcant dif-
ference between the control and TB groups.noise-dominated coefﬁcients. This thresholding step therefore
greatly reduces the dimensionality of the data, whilst only dis-
carding data which are unlikely to aid disease prediction.
A 10-fold cross-validation was then applied, using 90% of the
data as a training set, and the remaining 10% as a test set. Within
each fold, a supervised feature selection step was performed to
identify which features in the training set are the best for disease
prediction. For this, a Wilcoxon rank sum test was used for each
feature in turn, selecting those with the lowest p-value (using a
training set only). Two features were extracted, which we have
found to be sufﬁcient in other studies. Predictions were then pro-
duced (disease/control) for the test set using just the two selected
features.
Four different classiﬁers were used for prediction: Sparse Lo-
gistic Regression, Gaussian Process Classiﬁer, Random Forest and
Support Vector Machine. Of these, the Gaussian Process Classiﬁer
generated the best classiﬁcation results. The Gaussian Process
classiﬁer outputs a predicted probability of a sample being from a
TB patient, from which a receiver operator curve (ROC) and per-
formance data were calculated.3. Results and discussion
Figure 1 shows the predictive probability using a Gaussian
Process Classiﬁer, showing a difference between the two groups (TB
patients and controls). It was noted that different analysis tech-
niques resulted in exactly the same sensitivity and speciﬁcity of 81%
and 79% respectively. Figure 2 shows the ROC using the same
analytical method. This result has an area under the curve of 0.92
(conﬁdence interval at 95%, 0.84 to 1). Interestingly, just analysing
the pulmonary TB patients gives a very similar result AUC ¼ 0.91
(0.81e1).
The sensitivity and speciﬁcity reported here are not as high as
previously reported using an electronic nose (sensitivity 93.5%,
speciﬁcity 85.3%) [15]. In this study, however, Bruins et al. only
included those with pulmonary TB, which may serve to reduce the
number of false negatives thereby increasing sensitivity. Moreover
they also excluded cases with HIV; we included 3 such cases.
Despite HIV-TB co-infection being a common global scenario, there
is a paucity of information on breath analysis in this context and
whether, as for atypical clinical presentations of TB, it may also alter
breath results.
Nevertheless, using this relatively crude sampling system, the
results indicate that FAIMS shows promise for TB detection. BreathFigure 2. Receiver Operator Curve (AUC ¼ 0.92; 95% CI: 084, 1) for breath analysis of
patients with TB.
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biota, thus potentially reducing the diagnostic yield in TB. However,
we are already in the process of improving our sample capture
system and we believe that improved results are achievable.
4. Conclusions
The results indicate that FAIMS, and Ion Mobility Spectrometry
(IMS) in particular, has potential as a technology that can be applied
to breath testing for clinical diseases including TB. We recognise
that we were limited by small sample sizes, sampling of whole
breath rather than end-tidal, and undertaking the study in optimal
UK hospital conditions as opposed to a low- or middle-income ﬁeld
setting. It is also difﬁcult to determine whether the chemicals being
detected were directly associated with the metabolism of the TB
pathogen, or the body's general response to infection. However,
there is considerable potential for utilising IMS as a simple, rapid,
cheap breath test for stratifying suspected TB patients. The ad-
vantages of IMS in terms of sensitivity, ease of setup with minimal
training and minimal instrumental drift and variability, may pro-
vide a solution for targeting TB treatment in a global context. We
are now looking to further study IMS technology in a more rigorous
way, testing its efﬁcacy for different breath capture techniques and
in a variety of clinical circumstances.
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